Canaccord Genuity Maintains Buy on Globus Medical, Lowers Price Target to $105

Benzinga · 3d ago
Canaccord Genuity analyst Caitlin Cronin maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $115 to $105.